We are live on ! Find out more
VanEck Associates

VanEck Associates Portfolio holdings

AUM $133B
1-Year Est. Return 72.99%
This Fund
S&P 500
This Quarter Est. Return
+30.34%
1 Year Est. Return
+72.99%
3 Year Est. Return
+157.94%
5 Year Est. Return
+206.35%
10 Year Est. Return
+770.56%
AUM
$14.8B
AUM Growth
+$2.24B
Cap. Flow
-$211M
Cap. Flow %
-1.42%
Top 10 Hldgs %
30.47%
Holding
845
New
82
Increased
442
Reduced
285
Closed
30

Top Buys

Rank Stock Value
1
B
Barrick Mining
B
+$161M
2
FNV icon
Franco-Nevada
FNV
+$70.4M
3
HMY icon
Harmony Gold Mining
HMY
+$61.6M
4
NEM icon
Newmont
NEM
+$52.8M
5
AG icon
First Majestic Silver
AG
+$43.3M

Top Sells

Rank Stock Value
1
SLB icon
SLB Ltd
SLB
+$84.1M
2
AU icon
AngloGold Ashanti
AU
+$63.6M
3
SE
Spectra Energy Corp Wi
SE
+$41.3M
4
QCOM icon
Qualcomm
QCOM
+$41M
5
WMT icon
Walmart Inc
WMT
+$40.5M

Sector Composition

Rank Sector Weight
1 Materials 48.33%
2 Energy 21.69%
3 Healthcare 7.09%
4 Industrials 3.11%
5 Communication Services 1.9%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
FXI icon
801
iShares China Large-Cap ETF
FXI
$4.37B
$26K ﹤0.01%
778
+282
+57% +$8.85K
GME icon
802
GameStop
GME
$9.75B
$24K ﹤0.01%
3,064
+464
+18% +$3.33K
MATV icon
803
Mativ Holdings
MATV
$481M
$23K ﹤0.01%
721
-13
-2% -$465
CRC
804
DELISTED
California Resources Corporation
CRC
$22K ﹤0.01%
2,152
-3,985
-65% -$47K
LGND icon
805
Ligand Pharmaceuticals
LGND
$5.76B
$19K ﹤0.01%
+284
New +$17.3K
IPXL
806
DELISTED
Impax Laboratories, Inc.
IPXL
$19K ﹤0.01%
+597
New +$21K
PCRX icon
807
Pacira BioSciences
PCRX
$1.04B
$17K ﹤0.01%
+314
New +$18.4K
NKTR icon
808
Nektar Therapeutics
NKTR
$2.39B
$16K ﹤0.01%
+79
New +$15.2K
WLK icon
809
Westlake Corp
WLK
$9.03B
$15K ﹤0.01%
331
+51
+18% +$2.31K
SYNH
810
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$15K ﹤0.01%
+373
New +$15.4K
CBM
811
DELISTED
Cambrex Corporation
CBM
$12K ﹤0.01%
+274
New +$10.8K
HALO icon
812
Halozyme
HALO
$9.79B
$9K ﹤0.01%
+911
New +$8.57K
PRAH
813
DELISTED
PRA Health Sciences, Inc.
PRAH
$8K ﹤0.01%
+178
New +$7.52K
EGRX
814
DELISTED
Eagle Pharmaceuticals, Inc.
EGRX
$3K ﹤0.01%
+81
New +$5.14K
INSY
815
DELISTED
Insys Therapeutics, Inc.
INSY
$3K ﹤0.01%
+211
New +$4.01K
AEIS icon
816
Advanced Energy
AEIS
$11.6B
-20,530
Closed -$580K
AME icon
817
Ametek
AME
$55.4B
-22,472
Closed -$1.2M
AXP icon
818
American Express
AXP
$227B
-501,366
Closed -$34.9M
BRK.B icon
819
Berkshire Hathaway Class B
BRK.B
$1.1T
-265,927
Closed -$35.1M
BTE icon
820
Baytex Energy
BTE
$3.25B
-29,073
Closed -$94K
CSW
821
CSW Industrials
CSW
$5.2B
-779
Closed -$29K
CTSH icon
822
Cognizant
CTSH
$24.9B
-23,330
Closed -$1.4M
EDC icon
823
Direxion Daily MSCI Emerging Markets Bull 3X ETF
EDC
$150M
-8,750
Closed -$403K
EPI icon
824
WisdomTree India Earnings Fund ETF
EPI
$2.06B
-30,000
Closed -$596K
HII icon
825
Huntington Ingalls Industries
HII
$12.9B
-230
Closed -$29K

Similar funds

VanEck Associates's Q1 2016 Portfolio in Review

As of Q1 2016, VanEck Associates held 845 positions worth $14.8B, up 18% from $12.6B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

VanEck Associates's Q1 2016 filing shows 82 new, 442 increased, 285 reduced and 30 closed positions. Its largest new stake was LinkedIn Corporation: 282,263 shares worth $32.3M. The largest sale was SLB Ltd, an estimated $84.1M.

By sector, the portfolio is most concentrated in Materials at 48% of assets, up from 39% a quarter earlier, followed by Energy and Healthcare.

  • VanEck Associates's largest Q1 2016 buy was LinkedIn Corporation: 282,263 shares worth $32.3M.
  • VanEck Associates added most to Barrick Mining in Q1 2016, an estimated $161M increase.
  • VanEck Associates's biggest Q1 2016 reduction was SLB Ltd, cutting an estimated $84.1M.
  • VanEck Associates fully exited IBM in Q1 2016, selling an estimated $35.3M.
  • VanEck Associates's ten largest holdings make up 30% of its $14.8B portfolio in Q1 2016.
  • VanEck Associates opened 82 new positions and closed 30 in Q1 2016.
  • VanEck Associates's portfolio value rose 18% quarter-over-quarter to $14.8B.

Based on VanEck Associates's 13F filing for Q1 2016, filed 13 May 2016.